| Reference, consortium | Total cases | Total controls | Exposure | Exposure metric | Overall NHL (OR, 95% CI) | Diffuse (OR, 95% CI) | FL (OR, 95% CI) | CLL/SLL (OR, 95% CI) | Reference |
| Morton et al., InterLymph | 6594 | 8892 | Smoking | Ever smoker | 1.07 (1.00–1.15) | 1.09 (0.99–1.20) | 1.15 (1.02–1.29) | 1.01 (0.86–1.18) |
[15] | ≥31 cigs/day | 1.07 (0.93–1.23) | 1.13 (0.92–1.38) | 0.95 (0.73–1.23) | 0.82 (0.59–1.14) | ≥36 years | 1.16 (1.05–1.28) | 1.13 (0.97–1.31) | 1.28 (1.08–1.53) | 1.16 (0.95–1.42) | ≥36 pack-yrs | 1.21 (1.09–1.34) | 1.24 (1.06–1.44) | 1.30 (1.08–1.56) | 1.11 (0.89–1.38) |
|
Besson et al., EpiLymph | 1742 | 2465 | Smoking | Ever smoker | 1.06 (0.92–1.21) | 0.88 (0.72–1.09) | 1.16 (0.87–1.56) | 1.08 (0.83–1.39) |
[17] | ≥20 cigs/day | 1.05 (0.88–1.26) | 0.95 (0.72–1.24) | 1.21 (0.83–1.78) | 0.89 (0.64–1.22) | >32 years | 1.15 (0.96–1.39) | 0.91 (0.68–1.22) | 1.39 (0.94–2.06) | 1.10 (0.81–1.50) | ≥27 pack-yrs | 1.13 (0.94–1.37) | 1.04 (0.78–1.38) | 1.21 (0.81–1.82) | 1.01 (0.73–1.39) |
|
Morton et al., InterLymph | 6492 | 8683 | Alcohol | Ever drinker | 0.83 (0.76–0.89) | 0.75 (0.66–0.84) | 0.84 (0.73–0.97) | 0.94 (0.79–1.13) |
[22] | ≥28 servings/week | 0.87 (0.76–0.99) | 0.73 (0.60–0.90) | 0.82 (0.63–1.07) | 1.16 (0.88–1.52) | ≥401 kg lifetime consumption | 0.80 (0.68–0.95) | | | | ≥41 years | 0.81 (0.69–0.95) | 0.67 (0.53–0.85) | 0.84 (0.63–1.12) | 0.81 (0.58–1.15) |
| Besson et al., EpiLymph | 1742 | 2465 | Alcohol | Ever regular drinker | 0.99 (0.84–1.18) | 0.89 (0.69–1.15) | 0.96 (0.65–1.44) | 1.18 (0.87–1.59) |
[17] | >730 grams per month | 0.90 (0.71–1.15) | 0.74 (0.51–1.07) | 1.15 (0.67–1.99) | 0.94 (0.62–1.41) | ≥ 378 kg lifetime consumption | 0.99 (0.78–1.26) | 0.82 (0.57–1.19) | 1.12 (0.63–2.00) | 1.04 (0.69–1.55) | > 42 years duration | 0.88 (0.68–1.12) | 0.68 (0.46–1.02) | 1.20 (0.67–2.16) | 1.06 (0.73–1.55) |
|
Kricker et al., InterLymph | 8243 | 9697 | Sun exposure | Composite total sun exposure | 0.87 (0.71–1.05)1 | | | |
[23] | Composite recreational sun exposure | 0.76 (0.63–0.91) | 0.69 (0.55–0.87) | 0.73 (0.62–0.86) | 0.83 (0.59–1.17) | Composite nonrecreational sun exposure | 1.01 (0.89–1.15) | | | | Lifetime, total exposure | 0.88 (0.69–1.11) | | | | Lifetime, recreational | 0.79 (0.54–1.14) | | | | Lifetime, nonrecreational | 0.98 (0.84–1.15) | | | | Age 10–17, total exposure | 0.76 (0.56–1.03) | | | | Age 10–17, recreational | 0.85 (0.62–1.16) | | | | Age 10–17, nonrecreational | 0.87 (0.66–1.15) | | | | Age 18–40, total exposure | 0.93 (0.82–1.06) | | | | Age 18–40, recreational | 0.80 (0.68–0.94) | | | | Age 18–40, nonrecreational | 0.97 (0.85–1.10) | | | | 10 years before diagnosis, total | 0.84 (0.72–0.97) | | | | 10 years before diagnosis, recreational | 0.74 (0.62–0.88) | | | | 10 years before diagnosis, nonrecreational | 0.98 (0.85–1.14) | | | |
|
Boffetta et al., EpiLymph | 1518 | 2124 | UV radiation | Personal exposure, free days childhood | 1.07 (0.81–1.43)1 | 0.88 (0.60–1.28) | 1.35 (0.80–2.26) | 1.17 (0.70–1.97) |
[24] | Personal exposure, school days childhood | 1.01 (0.76–1.35) | 0.71 (0.45–1.14) | 0.90 (0.46–1.77) | 1.44 (0.89–2.34) | Personal exposure, free days adulthood | 0.76 (0.61–0.95) | 0.62 (0.44–0.87) | 0.78 (0.47–1.27) | 0.76 (0.44–1.31) | Personal exposure, workdays adulthood | 0.97 (0.73–1.29) | 0.93 (0.60–1.43) | 0.81 (0.37–1.77) | 0.91 (0.47–1.73) | Occupational exposure, duration years (UV natural) | 0.97 (0.73–1.30) | 0.63 (0.37–1.04) | 0.61 (0.33–1.11) | 1.27 (0.89–1.82) | Occupational exposure, duration years (UV artificial) | 1.14 (0.77–1.70) | 0.90 (0.45–1.79) | 1.92 (0.85–4.31) | 0.90 (0.45–1.78) | Sunlamp use | 0.69 (0.51–0.93) | 0.63 (0.38–1.03) | 0.71 (0.41–1.24) | 0.99 (0.58–1.70) |
|
Cocco et al., EpiLymph | 2348 | 2462 | Solvents | Ever exposed | B-NHL: 1.1 (1.0–1.3); T-lymphoma: 0.9 (0.7–1.4) | 1.0 (0.8–1.2) | 1.3 (1.0–1.7) | 1.3 (1.1–1.6) |
[25] | High frequency of exposure | B-NHL: 1.5 (1.2–1.8); T-lymphoma: 1.7 (0.9–3.0) | 1.1 (0.7–1.6) | 2.0 (1.3–3.2) | 1.5 (1.0–2.3) | High exposure intensity | B-NHL: 1.2 (0.9–1.7); T-lymphoma: 1.6 (0.8–3.3) | 1.2 (0.7–1.8) | 1.4 (0.7–2.6) | 1.2 (0.7–2.0) | High duration of exposure | B-NHL: 1.2 (1.0–1.4); T-lymphoma: 1.1 (0.6–1.8) | 1.0 (0.8–1.4) | 1.3 (0.8–1.9) | 1.3 (1.0–1.8) | High cumulative exposure | B-NHL: 1.3 (1.1–1.6); T-lymphoma: 1.2 (0.7–2.0) | 1.3 (0.9–1.7) | 1.7 (1.1–2.5) | 1.5 (1.1–2.1) |
|
Zhang et al., InterLymph | 4461 | 5799 | Hair dye | Ever use | 1.1 (1.0–1.3)2 | 1.0 (0.9–1.2) | 1.3 (1.0–1.6) | 1.3 (1.0–1.6) |
[26] | Permanent dye | 1.1 (1.0–1.3) | 1.0 (0.8–1.2) | 1.3 (1.1–1.7) | 1.2 (0.9–1.6) | Nonpermanent | 1.2 (1.0–1.4) | 1.1 (0.9–1.4) | 1.3 (1.0–1.7) | 1.3 (0.9–1.7) | Permanent dark | 1.1 (0.9–1.3) | 0.9 (0.7–1.1) | 1.4 (1.1–1.8) | 1.3 (0.9–1.7) | Permanent light | 1.2 (1.0–1.4) | 1.0 (0.8–1.3) | 1.3 (1.0–1.7) | 1.3 (0.9–1.8) | Nonpermanent dark | 1.2 (1.0–1.5) | 1.1 (0.9–1.4) | 1.4 (1.0–1.8) | 1.3 (0.9–1.8) | Nonpermanent light | 1.2 (0.9–1.5) | 1.1 (0.8–1.6) | 1.2 (0.8–1.9) | 1.7 (1.0–2.7) | <1980, ever | 1.3 (1.1–1.4) | 1.1 (0.9–1.3) | 1.4 (1.1–1.9) | 1.5 (1.1–2.0) | <1980, permanent dark | 1.3 (1.0–1.5) | 1.0 (0.8–1.3) | 1.4 (1.0–1.9) | 1.5 (1.0–2.2) | <1980, permanent light | 1.3 (1.1–1.6) | 1.1 (0.9–1.5) | 1.6 (1.2–2.2) | 1.5 (1.0–2.2) | <1980, nonpermanent dark | 1.2 (1.0–1.6) | 1.0 (0.7–1.4) | 1.2 (0.8–1.8) | 1.6 (1.0–2.5) | <1980, nonpermanent light | 1.3 (0.9–1.9) | 1.0 (0.6–1.7) | 1.7 (1.0–3.0) | 1.9 (1.1–3.6) | ≥1980, ever | 1.1 (0.9–1.2) | 1.0 (0.8–1.2) | 1.3 (1.0–1.7) | 1.1 (0.8–1.5) | ≥1980, permanent dark | 1.0 (0.8–1.2) | 0.7 (0.5–1.0) | 1.5 (1.1–2.1) | 1.1 (0.7–1.8) | ≥1980, permanent light | 1.0 (0.8–1.3) | 1.0 (0.7–1.3) | 1.2 (0.8–1.8) | 0.9 (0.5–1.7) | ≥1980, nonpermanent dark | 1.3 (1.0–1.6) | 1.2 (0.9–1.6) | 1.7 (1.1–2.4) | 1.3 (0.8–2.1) | ≥1980, nonpermanent light | 1.1 (0.7–1.6) | 1.1 (0.6–1.9) | 1.0 (0.5–2.1) | 1.8 (0.9–3.7) |
|
de Sanjosé et al., EpiLymph | 2302 | 2417 | Hair dye | Ever use | 1.24 (1.01–1.53)3 | 0.96 (0.72–1.27) | 1.33 (0.90–1.96) | 1.43 (1.01–2.03) |
[27] | Dark dye | 1.26 (1.00–1.58) | | | | Light dye | 1.27 (1.00–1.60) | | | | Permanent | 1.24 (1.00–1.53) | | | | Wash-out (rinse) | 1.38 (1.07–1.77) | | | | ≥18 years use | 1.31 (1.02–1.67) | | | | ≥14 years use, dark | 1.50 (1.10–2.05) | | | | ≥12 uses per year | 1.33 (1.02–1.74) | | | | Ever, <1980 | 1.37 (1.09–1.72)4 | | | | Ever, ≥1980 | 1.11 (0.92–1.34) | | | | Dark, <1980 | 1.33 (1.01–1.75) | | | | Dark, ≥1980 | 1.17 (0.93–1.47) | | | | Light, <1980 | 1.27 (0.96–1.68) | | | | Light, ≥1980 | 1.13 (0.88–1.45) | | | | Permanent, <1980 | 1.27 (1.00–1.62) | | | | Permanent, ≥1980 | 1.14 (0.92–1.41) | | | | Wash-out, <1980 | 1.62 (1.16–2.27) | | | | Wash-out, ≥1980 | 1.14 (0.89–1.47) | | | | >10 years use, <1980 | 1.34 (1.04–1.71) | | | | >10 years use, ≥1980 | 1.24 (0.94–1.64) | | | |
|
Willett et al., InterLymph | 10453 | 16507 | Obesity | <18.5 BMI | 0.88 (0.71–1.08) | 0.90 (0.65–1.24) | 0.96 (0.62–1.48) | 1.19 (0.69–2.03) |
[28] | 25–29.99 BMI | 0.95 (0.85–1.07) | 0.97 (0.81–1.15) | 0.99 (0.84–1.15) | 0.96 (0.81–1.15) | 30–39.99 BMI | 0.97 (0.81–1.15) | 1.02 (0.82–1.26) | 1.07 (0.86–1.33) | 1.09 (0.84–1.42) | ≥40 BMI | 0.99 (0.70–1.41) | 1.80 (1.23–2.62) | 1.34 (0.69–2.63) | 1.11 (0.56–2.19) | Per 5 mg/k2 + | 0.96 (0.89–1.04) | 1.00 (0.90–1.10) | | |
|
|